本帖最后由 老马 于 2012-1-13 21:20 编辑
# \5 `5 r6 r3 v* Y7 @
! X) Z% S2 {7 q: \5 c9 w+ {. O爱必妥和阿瓦斯丁的比较" d2 a# d1 n) h. F7 d9 A/ z5 }
5 D R5 w N; l6 ?http://cancergrace.org/lung/2008/08/30/bms099-os-neg/! c$ M2 `7 T+ R+ ]
4 x5 O; Q% F1 [6 a) ?! _7 G- i2 z7 }
0 R; |: B- @( }8 m; `; K. a$ J
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/' W3 p6 N# o" q
==================================================: ` P* R& o% s
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)' Z! Y: p& P. x
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.- f) M/ C, n8 k! b
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
- U' h# m/ R, B9 \# q
|